Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Multiple myeloma (MM)

Nuclear SET domain-containing protein 2 (NSD2; MMSET; WHSC1)

Mouse and cell culture studies suggest inhibiting NSD2 activity could help treat t(4;14)-translocated MM. t(4;14) translocations are found in about 10%-20% of MM cases and drive overexpression of NSD2 and fibroblast growth factor receptor 3 (FGFR3; CD333). In MM cell lines with the t(4;14) translocation, small hairpin RNA knockdown of NSD2 decreased proliferation on and adherence to bone marrow stroma compared with no knockdown. In mice injected with MM cells that had doxycycline-inducible NSD2 knockdown, doxycycline decreased tumorigenesis and disease progression compared with no treatment. Next steps could include developing inhibitors of NSD2 (see NSD2 momentum, page 1).

SciBX 6(39); doi:10.1038/scibx.2013.1090
Published online Oct. 10, 2013

Patent and licensing status undisclosed

Huang, Z. et al. Cancer Res.; published online Aug. 26, 2013;
doi:10.1158/0008-5472.CAN-13-1000
Contact: Min Hu, Novartis Institutes for BioMedical Research,
Shanghai, China
e-mail:

min.hu@novartis.com